

Outpatient Management of COVID 19 Patients  
Bamlanivimab  
January 2021

- Bamlanivimab is a monoclonal antibody that has received FDA emergency use authorization for treatment of mild to moderate COVID 19 in patients 12 year of age and older and weighing at least 40 kg who are at risk for progressing to severe COVID 19 and/or hospitalization.
  - EUA high risk definitions:
    - Meet at least one of the following criteria:
      - Have a body mass index (BMI)  $\geq 35$
      - Have chronic kidney disease
        - Have diabetes
        - Have immunosuppressive disease
        - Are currently receiving immunosuppressive treatment
        - Are  $\geq 65$  years of age
        - Are  $\geq 55$  years of age AND have o cardiovascular disease, OR o hypertension, OR o chronic obstructive pulmonary disease/other chronic respiratory disease.
    - Are 12 – 17 years of age AND have
      - BMI  $\geq 85$ th percentile for their age and gender based on CDC growth charts, [https://www.cdc.gov/growthcharts/clinical\\_charts.htm](https://www.cdc.gov/growthcharts/clinical_charts.htm), OR
      - sickle cell disease, OR
      - congenital or acquired heart disease, OR o neurodevelopmental disorders, for example, cerebral palsy, OR
      - a medical-related technological dependence, for example, tracheostomy, gastrostomy, or positive pressure ventilation (not related to COVID-19), OR
      - asthma, reactive airway or other chronic respiratory disease that requires daily medication for control.
  - It is not authorized of use in patients
    - Who are hospitalized due to COVID-19
    - Who require oxygen therapy due to COVID-19
    - Who require an increase in baseline oxygen flow rate due to COVID-19
    - Those on chronic oxygen therapy due to underlying COVID-19 related comorbidity
- **Arkansas Children's Hospital Criterial for Use (see page 2 for full COVID 19 treatment pathway)**
  - Bamlanivimab use will be restricted to Infectious Disease
- Administration
  - Dosage: 700 mg IV as a one-time infusion
  - Must be administered within 5 days of symptom onset
- **Scheduling/Clinic Visits**
  - Patients will be required to be seen either via in person or telemedicine visit by an ACH Infectious Disease provider. **Please contact ID Section during normal business hours at 501-364-1416 to schedule a visit.**
  - Patients will be scheduled through the Infusion Center with medications administered by Infusion Center staff
  - Location – Infusion Center

# COVID-19 Treatment Pathway



**\*Refer to the following page for details regarding eligibility, treatment, and dosing**

## COVID-19 Treatment Agents

Medication (recommended or authorized)	Recommended Dose and Comments
<b>Corticosteroids</b>	Dexamethasone <b>0.15</b> mg/kg (max <b>6</b> mg) IV or PO once daily (preferred) OR Equivalent dose of substitute – methylprednisolone <b>0.8</b> mg/kg (max <b>32</b> mg) IV once daily  <b>Duration</b> 10 days or until discharge
<b>Remdesivir (Veklury®)</b>  <i>ID Consult Required</i>	3.5-40 kg: <b>5</b> mg/kg IV on day 1 then <b>2.5</b> mg/kg IV once daily on day 2 – 5 (or 10) ≥ 40 kg: <b>200</b> mg IV on day 1 then <b>100</b> mg IV once daily on day 2 – 5 (or 10) <b>Duration:</b> 5 or 10 days  <b>Indication:</b> Hospitalized patients confirmed COVID (+) requiring supplemental oxygen <b>Exclusion:</b> Renal impairment – Age > 28 days with eGFR < 30 mL/min Age 7-28 days with Cr > 1 mg/dL Hepatic impairment – ALT > 5x upper limit of normal
<b>Bamlanivimab</b> - SARS-CoV-2 Monoclonal antibody  <i>ID Consult Required</i>	<b>Outpatient therapy only – Call ID for procedure – 501-364-1416</b> <b>700</b> mg IV x1 (no additional doses)  <b>Inclusion criteria:</b> <ul style="list-style-type: none"> <li>• Outpatient</li> <li>• High risk – <b>see bottom row</b></li> <li>• Age ≥ 12</li> <li>• weight ≥ 40 kg</li> <li>• Within 5 days of symptom onset</li> </ul> <b>Exclusion criteria:</b> <ul style="list-style-type: none"> <li>• Hospitalized</li> <li>• New O2 requirement</li> <li>• Increased O2 from baseline</li> </ul> <b>**Patients receiving SARS-CoV-2 monoclonal antibodies cannot receive SARS-CoV-2 vaccination for 3 months</b>
<b>Anakinra (Kineret®)</b> - IL-1 receptor antagonist  <i>Rheum Consult Required</i>	4-10 mg/kg/day IV divided every 6-12 hours <b>Duration:</b> Response-dependent
<b>High-risk Patients</b> <ul style="list-style-type: none"> <li>• Sick cell disease with history of acute chest syndrome</li> <li>• Moderate-severe or uncontrolled obstructive lung disease (asthma, CF, other)</li> <li>• Primary immunodeficiency or severe immunocompromised state (AIDS)</li> <li>• Solid organ or bone marrow transplant recipient</li> <li>• Mechanical respiratory device-dependent</li> </ul>	

### Not recommended for treatment of COVID-19

- Hydroxychloroquine
- Azithromycin
- Lopinavir-ritonavir
- Ivermectin